Skip to main content
Toggle navigation
Search
Home
Back
Tweet
Glenn Kroog, n/a
Clinical Sciences
Regeneron Pharmaceuticals, Inc
Poster(s):
P-029: Pharmacokinetics (PK) and immunogenicity of linvoseltamab in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in LINKER-MM1
Thursday, September 26, 2024